Clinical Trials Browser

Phase 1 × Lymphoma × ibrutinib × Clear all

NCT04739813 2026-04-29

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

55 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Phase 1 Completed

15 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03876028 2023-01-31

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Phase 1 Terminated

10 enrolled

Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02756247 2022-10-10

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Phase 1 Completed

37 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02269085 2019-02-28

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Phase 1 Terminated

8 enrolled

Lymphoid

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT02780830 2016-09-15

INHIBITOR

Phase 1 Withdrawn

Lymphoid

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00849654 2013-05-22

PCYC-04753

Phase 1 Completed

66 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoid, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell